ISSN: 0094-6176
Journal Home
Journal Guideline
Seminars in Thrombosis and Hemostasis Q2 Unclaimed
Seminars in Thrombosis and Hemostasis is a journal indexed in SJR in Hematology and Cardiology and Cardiovascular Medicine with an H index of 116. It has an SJR impact factor of 0,745 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,745.
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy:
Type of publications:
Publication frecuency: -
- €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
0,745
SJR Impact factor116
H Index177
Total Docs (Last Year)333
Total Docs (3 years)12099
Total Refs986
Total Cites (3 years)260
Citable Docs (3 years)3.19
Cites/Doc (2 years)68.36
Ref/DocOther journals with similar parameters
Thrombosis Research Q2
Cancer Control Q2
Annals of Hematology Q2
Platelets Q2
Transfusion Medicine Reviews Q2
Compare this journals
Aims and Scope
Best articles by citations
Factor Xa Is a Superior Target to Factor IIa for Antithrombotic Therapies
View moreVenous Thromboembolism and Its Treatment in High-Risk Groups
View moreA Reliable von Willebrand Factor: Ristocetin Cofactor Enzyme-Linked Immunosorbent Assay to Differentiate between Type 1 and Type 2 von Willebrand Disease
View moreAnticoagulants in Thrombosis and Cancer: The Missing Link
View moreVenous Thromboembolism in Medical Patients-The Scope of the Problem
View moreClinical Aspects of the Different Forms of Viral Hepatitis and Their Treatment
View moreVirus Safety of Hemophilia Treatment in Germany and Austria-a Review of the Past 15 Years: A Eulogy for the 70th birthday of Professor Dr. rer. nat. Norbert Heimburger
View moreVirus Safety of Hemophilia Treatment in Germany and Austria: A Tribute to Norbert Heimburger, Ph.D.
View moreVirus Safety of Pasteurized Clotting Factor Concentrates
View moreDevelopment of Direct Thrombin Inhibitors in Comparison with Glycosaminoglycans
View moreLow-Molecular-Weight Heparin or Oral Anticoagulation for Secondary Prevention of Deep Vein Thrombosis in Cancer Patients
View moreLow-Molecular-Weight Heparins: Beyond Thrombosis in the Management of the Cancer Patient
View moreGreetings from the German Hemophilia Society and from the Gesellschaft fur Thrombose- und Hämostaseforschung
View morevon Willebrand Factor Collagen-Binding (Activity) Assay in the Diagnosis of von Willebrand Disease: A 15-Year Journey
View moreSuccessful Treatment of Patients with von Willebrand Disease using a High-Purity Double-Virus Inactivated Factor VIII/von Willebrand Factor Concentrate (Immunate®)
View moreUpper Extremity Deep Venous Thrombosis
View moreMALDI Mass Spectrometry as a Tool for Characterizing Glycosaminoglycan Oligosaccharides and their Interaction with Proteins
View morePrevention of Venous Thromboembolism: Focus on Mechanical Prophylaxis
View moreReduction in Thrombus Extension and Clinical End Points in Patients after Initial Treatment for Deep Vein Thrombosis with the Fixed-Dose Body Weight-Independent Low Molecular Weight Heparin Certoparin
View moreAlterations in Fibrin Structure in Patients with Liver Diseases
View moreAntithrombin Attenuates Microvascular Leakage and Leukocyte-Endothelial Interaction in Response to Endotoxin
View moreSixteen Years of Treatment with Pasteurized Human Clotting Factor Concentrates in Children and Adolescents: A Pharmacosurveillance Investigation Comprising 727 Patient Years
View moreRegulatory Role of Cytokines in Disseminated Intravascular Coagulation
View moreMolecular Weight-Dependent Influence of Heparin on the Form of Tissue Factor Pathway Inhibitor Circulating in Plasma
View more
Comments